A Case Report: Idiopathic or Drug-Induced Autoimmune Hepatitis-Can We Draw a Line?
AIH
DILI
acute hepatitis
drug-induced autoimmune hepatitis
Journal
Clinics and practice
ISSN: 2039-7275
Titre abrégé: Clin Pract
Pays: Switzerland
ID NLM: 101563282
Informations de publication
Date de publication:
13 Nov 2023
13 Nov 2023
Historique:
received:
11
09
2023
revised:
31
10
2023
accepted:
08
11
2023
medline:
21
11
2023
pubmed:
21
11
2023
entrez:
21
11
2023
Statut:
epublish
Résumé
Idiosyncratic drug-induced liver injury (DILI) is an unpredictable reaction of individuals exposed to a certain drug, and drug-induced autoimmune hepatitis (DIAIH) presents a DILI phenotype that mimics idiopathic autoimmune hepatitis (AIH) when considering the clinical, biochemical, serological and histological parameters. We present a case report of a 48-year-old male who was hospitalized due to severe hepatocellular liver injury two months after self-treatment with a muscle-building dietary supplement based on arginine-alpha-ketoglutarate, L-citrulline, L tyrosine, creatine malate and beet extract. His immunology panel was positive with increased IgG levels, and radiologic methods showed no signs of chronic liver disease. He underwent corticosteroid treatment with adequate response. After therapy withdrawal, a clinical relapse occurred. Seven months after the initial presentation, liver MR suggested initial cirrhotic changes in the right liver lobe. A liver biopsy revealed abundant lymphoplasmacytic infiltrate with piecemeal necrosis and grade 2 fibrosis. He responded well to the corticosteroid treatment again, and was further treated with low-dose prednisone without additional relapses. Several years later, further management confirmed the presence of liver cirrhosis with no histological or biochemical signs of disease activity. DIAIH is a DILI phenotype that is difficult to distinguish from idiopathic AIH despite a wide armamentarium of diagnostic methods. It should always be considered among the differential diagnoses in patients presenting with hepatocellular liver injury.
Identifiants
pubmed: 37987426
pii: clinpract13060125
doi: 10.3390/clinpract13060125
pmc: PMC10660691
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1393-1399Références
Clin Res Hepatol Gastroenterol. 2022 Dec;46(10):102009
pubmed: 35977662
J Hepatol. 2022 Feb;76(2):435-445
pubmed: 34688732
Eur Rev Med Pharmacol Sci. 2023 Feb;27(3):999-1006
pubmed: 36808345
J Dig Dis. 2018 Sep;19(9):514-521
pubmed: 29808546
Ann Intern Med. 2013 Oct 1;159(7):503-4
pubmed: 24081297
Gastroenterology. 2013 Jun;144(7):1419-25, 1425.e1-3; quiz e19-20
pubmed: 23419359
Hepatology. 1995 Jul;22(1):82-7
pubmed: 7601437
J Hepatol. 2019 Jun;70(6):1222-1261
pubmed: 30926241
Clin Exp Gastroenterol. 2019 Jul 29;12:349-354
pubmed: 31534356
J Clin Transl Hepatol. 2019 Mar 28;7(1):21-26
pubmed: 30944815
Gastroenterology. 2008 Dec;135(6):1924-34, 1934.e1-4
pubmed: 18955056
World J Gastroenterol. 2010 Feb 28;16(8):934-47
pubmed: 20180231
Int J Mol Sci. 2017 Sep 12;18(9):
pubmed: 28895915
Nat Rev Gastroenterol Hepatol. 2011 Aug 23;8(10):540-2
pubmed: 21862981
J Hepatol. 2021 Jul;75(1):86-97
pubmed: 33539847
Hepatology. 2011 Sep 2;54(3):931-9
pubmed: 21674554
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1635-1636
pubmed: 28535988
Dig Dis Sci. 2011 Apr;56(4):958-76
pubmed: 21327704
Clin J Gastroenterol. 2016 Jun;9(3):156-9
pubmed: 27170297
Clin Pharmacol Ther. 2011 Jun;89(6):806-15
pubmed: 21544079
Semin Liver Dis. 2014 May;34(2):194-204
pubmed: 24879983